Document 368-5 Filed 04/10/2007 Page 1 of 4

Exhibit 4

2	CHANCERY DIVISION HC 1999 No. 03241 PATENTS COURT
3	
4	Royal Courts of Justice Wednesday, 6th February 2002
5	
6	Before:
7	MR. JUSTICE NEUBERGER
8	
	HOECHST MARION ROUSSEL
9	Claimants/Petitioners
10	v.
11	KIRIN-AMGEN INC. & OTHERS
12	Defendants/Patentees
13	
14	(Computer-aided transcript of the Stenograph Notes of
15	Marten Walsh Cherer Limited, Midway House 27/29 Cursitor Street, London EC4A 1LT
16	Telephone Number 0207 405 5010. Fax Number 0207 405 5026)
17	
l	
18	
19	MR. ANTONY WATSON QC and MR. ANDREW WAUGH QC and MR. TOM HINCHLIFFE (instructed by Messrs.
20	Taylor Joynson Garrett) appeared on behalf of Kirin-Amgen.
21	MR. DAVID KITCHIN QC and MR. RICHARD MEADE and MISS LINDSAY LANE
22	(instructed by Messrs. Bird & Bird) appeared on behalf of the TKT parties.
23	
24	·
25	PROCEEDINGS DAY 3

HOECHST v KIRIN

6 FEBRUARY 2002

DAY 3

1		i	
1	BORUN - KITCHIN	1	BORUN - KITCHIN
2	I am not apportioning blame to anybody.	2	scientific counselling by at least Dr. Fritsch.
3	MR. KITCHIN: I have nearly come to an end, my Lord.	3	Q. Do you know if he had the Egrie input file with him?
4	A. In A2, tab 2, page 159, around line 45 we are talking about	4	A. 1 know he was aware of it.
5	the yeast expression product that says "Preliminary analysis	5	Q. But you have no idea
6	(Reads to the words) and relatively high mannose	6	MR. JUSTICE NEUBERGER: Wait a minute.
7	content of the associated carbohydrate."	7	A. I do not know if he had it with him and I do not know if Gl's
8	Q. So that would provide a basis for getting some sort of claim	8	patent counsel, who was also there - I am afraid his name
9	to yeast?	9	escapes me was familiar with the interference.
10	A. That would provide a basis for getting a claim to recombinant	10	MR. JUSTICE NEUBERGER: You believed that Dr. Fritsch had seen
11	products that are glycosylated and that differ in terms of	11	it.
12	their glycosylation from urinary products, which are the	12	A. I do believe that.
13	prior art products.	13	Q. You did not know whether he had it with him or not but you
14	Q. At any rate, whether that is right or wrong was not explored	14	believed at some point he had seen it. Why did you believe
15	with the board, but what you did have basis for was the SDS	15	that and what was that based on?
16	comparison on page 146. That you chose to rely upon, did you	16	A. Because it appeared to me that the entire Boehringer Mannheim
17	not?	17	series of arguments was being formulated by Genetics
18	A. Yes, we did. It was in Prof. Cummings's chart. It was in	18	Institute and not by the counsel that was nominally
19	our briefs, and we relied on it.	19	representing them. The arguments were very familiar, almost
, 20	Q. I suggest to you that when you relied upon that statement and	20	identical to those raised in the interference on the issue of
21	you had access to all your scientists present, you knew that	21	whether or not urinary EPO and recombinant EPO were
22	the statement in the patent was not right with regard to COS?	22	different
23	A. I reject that suggestion.	23	MR. KITCHIN: Do you have any knowledge as to whether or not
24	Q. You had filed the two declarations from Dr. Egrie in 1991 and	24	Dr. Fritsch was free to use the Egrie input file in
25	the brief yourself in 1991 indicating that COS and urinary	25	connection with the European Patent Office proceedings?
1	,		
	453		455
,		 	PONIAL KITCHIN
1	BORUN - KITCHIN	1	BORUN - KITCHIN
2	migrated to the same extent on SDS?	2	A. I do not. I believe it was one of the trial exhibits in
2	migrated to the same extent on SDS? A. I agree with that.	2 3	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all
2 3 4	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen	2 3 4	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with
2 3 4 5	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen scientist supporting a statement that COS has a higher	2 3 4 5	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in
2 3 4 5 6	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen scientist supporting a statement that COS has a higher apparent molecular weight than urinary EPO.	2 3 4 5 6	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like
2 3 4 5 6 7	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen scientist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my	2 3 4 5 6 7	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps
2 3 4 5 6 7 8	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen scientist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who	2 3 4 5 6 7 8	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially
2 3 4 5 6 7 8 9	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen scientist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the	2 3 4 5 6 7 8 9	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the
2 3 4 5 6 7 8 9	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen scientist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or	2 3 4 5 6 7 8 9	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time.
2 3 4 5 6 7 8 9 10	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal ——	2 3 4 5 6 7 8 9 10	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to
2 3 4 5 6 7 8 9 10	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I	2 3 4 5 6 7 8 9 10 11 12	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie
2 3 4 5 6 7 8 9 10 11 12 13	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but	2 3 4 5 6 7 8 9 10 11 12 13	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that.
2 3 4 5 6 7 8 9 10 11 12 13 14	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point.	2 3 4 5 6 7 8 9 10 11 12 13 14	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that
2 3 4 5 6 7 8 9 10 11 12 13 14	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have
2 3 4 5 6 7 8 9 10 11 12 13 14 15	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal — MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal — MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular weight as CHO recombinant EPO?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey hair. Their in-house patent counsel was there throughout the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular weight as CHO recombinant EPO? A. I reject that. That is contrary to facts in the papers that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey hair. Their in-house patent counsel was there throughout the proceedings.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular weight as CHO recombinant EPO? A. I reject that. That is contrary to facts in the papers that were being relied upon by our opponents.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey hair. Their in-house patent counsel was there throughout the proceedings. Q. Roche's In-house patent counsel or GI's?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular weight as CHO recombinant EPO? A. I reject that. That is contrary to facts in the papers that were being relied upon by our opponents. Q. How do you know that the Roche parties at the European Patent	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey hair. Their in-house patent counsel was there throughout the proceedings. Q. Roche's In-house patent counsel or GI's? A. GI's, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular weight as CHO recombinant EPO? A. I reject that. That is contrary to facts in the papers that were being relied upon by our opponents. Q. How do you know that the Roche parties at the European Patent Office had an opportunity to consider the Egrie input file?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey hair. Their in-house patent counsel was there throughout the proceedings. Q. Roche's in-house patent counsel or GI's? A. GI's, yes. MR. KITCHIN: The document is covered with "confidential" stamps.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	migrated to the same extent on SDS? A. I agree with that. Q. We have not been able to identify any evidence from any Amgen sclentist supporting a statement that COS has a higher apparent molecular weight than urinary EPO. A. In the experiment that was performed that was my understanding. I think it has been confirmed by others who have looked at the same gel. I think it is confirmed in the wording, albeit possibly ambiguous wording, of slightly or approximately equal —— MR. JUSTICE NEUBERGER: We are going over the same ground. I appreciate it is at a different stage in the process, but they are really the same point. MR. KITCHIN: They are. You also knew by this time that urinary EPO was highly variable. A. I do not understand that. Q. I suggest to you that you failed to disclose to the board what you knew about Lot 82 having the same apparent molecular weight as CHO recombinant EPO? A. I reject that. That is contrary to facts in the papers that were being relied upon by our opponents. Q. How do you know that the Roche parties at the European Patent	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I do not. I believe it was one of the trial exhibits in Boston. If it were a trial exhibit in Boston, then all confidentiality wraps would be off. And I would agree with you, let us put it this way, that the Egrie input document in and of itself without explanatory declarations and the like does not amount to much. It is just a collection of scraps of paper, some from notebooks, some written out especially for the purpose of whatever Dr. Egrie's purpose was at the time. MR. JUSTICE NEUBERGER: Just one point. You said in answer to Mr. Kitchin the reason you believed that Roche had the Egrie file was that Dr. Fritsch had got it and you explained that. Mr. Waugh was concerned, I think possibly rightly, that Mr. Kitchin unintentionally interrupted you. You might have been going to say some other person may have had it. I did not want you to miss that opportunity. A. I can certainly supply it to you tomorrow morning, my Lord,) but his name escapes me. He is this at all. He has grey hair. Their in-house patent counsel was there throughout the proceedings. Q. Roche's In-house patent counsel or GI's? A. GI's, yes.

33 (Pages 453 to 456)

MARTEN WALSH CHERER LTD 27/29 CURSITOR STREET TELEPHONE: 020 7405 5010

E-MAIL: martenwc@aol.com

LONDON EC4A 1LT FAX: 020 7405 5026

HOECHST v KIRIN

6 FEBRUARY 2002

DAY 3

	· · · · · · · · · · · · · · · · · · ·		
1	BROWN - KITCHIN	1	BROWN - KITCHIN
2	in our response to the appeals, we made the point that only	2	available. I am sure you know the rules, that you must not
3	prior art, only uEPO that was prior art was citable.	3	talk to anybody about the case. It will be 9.30, subject to
4	Q. I am not talking about that at all. I am talking about the	4	reconsideration.
5	position here.	5	(Adjourned at 4.35 till 9.30 tomorrow morning)
6	A. This is not prior art EPO. It cannot be.	6	(
7	MR. JUSTICE NEUBERGER: Just wait for the question.	7	
8	MR. KITCHIN: Thank you, Mr. Brown.	8	
9	A. I am sorry.	9	
10	Q. Could we have a look, please, together at this declaration	10	
11	which you submitted.	11	+
12	MR. JUSTICE NEUBERGER: How long is it going to take? Do you	12	
13	want to deal with it now or tomorrow morning.	13	
14	MR. KITCHIN: It might just take a minute or two, so shall we	14	
15		15	
1	take it in the morning?	ł	
16	MR. JUSTICE NEUBERGER: What time would you like to start in the	16	
17	morning?	17	
18	MR. KITCHIN: I am in your Lordship's hands.	18	
19	MR. JUSTICE NEUBERGER: From what I gather, the witness would	19	
- 20	rather start sooner than later. Would it seem sensible to	20	
21	start at ten o'clock.	21	
	MR. KITCHIN: Yes, my Lord.	22	
23	MR. JUSTICE NEUBERGER: Do you want to start earlier or not?	23	
24	MR. KITCHIN: Ten o'clock is certainly convenient for me, my	24	
25	Lord.	25	
	481		483
	401		465
		1	
1	BROWN - KITCHIN		
2	MR. JUSTICE NEUBERGER: Do you want to start earlier than that?		
3	If you want a minute to think about it		
4	MR. WAUGH: It would assist getting finished in a day. We would	1	
5	advocate a little earlier. There is no one witness who is		
6	going to be subjected to a long day tomorrow.		
7	MR. JUSTICE NEUBERGER: If we could start earlier, Mr. Waugh is	ł	
8	saying that would be better. You have got the brunt of it,		
9	because you have got this cross-examination and two others.	ŀ	
10	While it would be nice to finish on Thursday, I do not want		•
11	to be oppressive to you. I tell you what. I am going to say		
12	I will be ready to start at 9.30. If you do not want to	.	
13	start till ten o'clock, that is fine provided Mr. Watson and		
14	Mr. Waugh and everybody else knows by six o'clock whether you		
15	want to start at 9.30, 9.45 or 10 o'clock, I will leave it to		
16	you because you have the brunt of it.	1	
1	MR. KITCHIN: My junior is certainly going to take one of the	1	
18	witnesses, so that will assist.	ŀ	
19	MR. JUSTICE NEUBERGER: I would rather start earlier than later.		
20	MR. KITCHIN: Would your Lordship prefer to start at half-past	1	
21	nine?	1	
22	MR. KITCHIN: Half-past nine it is, my Lord.	-	
23	MR. JUSTICE NEUBERGER: It you do change your mind because you	1	
24	have the brunt of it, let Mr. Waugh and Mr. Watson know and	1	
25	make sure the witness knows. I will say 9.30, and I will be		
-	2 0 and relations relations. I will day years and a resident		
	482	,	
1		İ	

40 (Pages 481 to 483)

MARTEN WALSH CHERER LTD 27/29 CURSITOR STREET TELEPHONE: 020 7405 5010

E-MAIL: martenwc@aol.com

LONDON EC4A 1LT FAX: 020 7405 5026